Presents... Corporate Sponsorship Package

Transcription

1 Presents... Corporate Sponsorship Package

2 Presents... What: Annual fund raising event of the Kendall and Taylor Atkinson (KATA) Foundation. This year s event is a western-themed gala with silent and live auctions, food, dancing, and Texas Hold Em. When: Saturday, November 17, :00 pm Where: The Wyndham Hotel, Denver Tech Center Ticket Cost: $75.00 per person Event Contacts: Ken & Jeanne Atkinson ~ / Jack & Lisa Nash ~ ~ katafoundation@msn.com Website ~ Information and online auction can also be found at Blacktie-Colorado ~ $5,000 Platinum $2,500 Gold Sponsorship Opportunities Brave Bull Riders 14 tickets to Brave Hearts Hoot n Holler Company banner prominently displayed at the event Company name and logo prominently listed in the event program Listed on the event page of the KATA Foundation s website with a link to your company s website Buckin broncos 8 tickets to Brave Hearts Hoot n Holler Company banner prominently displayed at the event Company name and logo prominently listed in the event program Listed on the event page of the KATA Foundation s website with a link to your company s website $1,000 Silver $500 bronze rowdy wranglers 6 tickets to Brave Hearts Hoot n Holler Company name and logo prominently listed in the event program Listed on the event page of the KATA Foundation s website with a link to your company s website courageous calf ropers 4 tickets to Brave Hearts Hoot n Holler Company name and logo prominently listed in the event program Listed on the event page of the KATA Foundation s website with a link to your company s website Other sponsorship opportunities include: Chocolate Fountain Dessert Table: $1500 Silent Auction Tent: $800 Texas Hold Em Table: $300 Checks may be made payable to the KATA Foundation, PO Box 3514, Littleton, CO 80161

3 Kendall And Taylor Atkinson FOUNDATION Fighting Fanconi Anemia...Improving The Lives Of Children The Kendall and Taylor Atkinson Foundation (KATA) was established by Ken and Jeanne Atkinson in memory of their children, Kendall and Taylor, who lost their lives to Fanconi anemia (FA), a deadly genetic blood disease that usually ends in death before adulthood. Children who have a bone marrow transplant and survive into adulthood are at extremely high risk for many debilitating and deadly cancers. The primary mission of the Foundation is to raise much needed funds for treatment and research of Fanconi anemia. Curing Fanconi anemia has a broad scope of importance as research has shown a relationship between genetic activity of FA and breast, neck, head, other blood, and uterine cancers. Discoveries in FA genetic research have led to important break-throughs for these other cancers. So, while FA itself may be a rare disease, continued support for FA research has a broad impact on the cancer world at large. The money that KATA raises will be directed to the Fanconi Anemia Research Fund ( The tireless efforts of the Fanconi Anemia Research Fund have demonstrated that a rare genetic disorder can provide a vital key to understanding the basic biological process of cancer itself. The importance of these efforts to the advancement of medical science cannot be overstated. - Lee Hartwell, PhD, President and Director, Fred Hutchinson Cancer Research Center, Winner, Nobel Prize, 2001 In addition, the Kendall and Taylor Atkinson Foundation (KATA) seeks to improve the lives of children living with disability, disease, or poverty. In 2007, this smaller portion of the money raised will benefit Camp Barnabas ( a camp offering childhood experiences to children who have been robbed of them by disease or disability. KATA is governed by an eight member Board of Directors. In 2006, our combined administrative Kand fund raising Acosts were less than T6%. A PO Box 3514, Littleton, CO (303) katafoundation@msn.com The Kendall and Taylor Atkinson Foundation (KATA) is a 501(c)(3) tax-exempt organization designated by the Internal Revenue Code. Our tax identification number is

4 What is Fanconi Anemia? FANCONI ANEMIA FACTS Fanconi anemia (FA) is one of the inherited anemias that leads to bone marrow failure (aplastic anemia). It is a recessive disorder: if both parents carry a defect (mutation) in the same FA gene, each of their children has a 25% chance of inheriting the defective gene from both parents. When this happens, the child will have FA. Though considered primarily a blood disease, it can affect all systems of the body. Many patients eventually develop acute myelogenous leukemia (AML) and at a very early age. FA patients are extremely likely to develop gynecological, gastrointestinal, and/or head and neck squamous cell carcinomas, again at a much earlier age than in squamous cell carcinoma patients in the general population. Diagnosis Fanconi anemia usually reveals itself before children are 12 years old, but in rare cases no symptoms are present until adulthood. Fanconi anemia patients are usually smaller than average. They may feel extreme fatigue and have frequent infections. Nosebleeds or easy bruising may be a first sign of the disease. Blood tests may reveal a low white cell, red cell or platelet count or other abnormalities. Sometimes myelodysplasia, AML, or squamous cell carcinoma in a young adult is the first sign of FA. Also, physical defects may alert a physician to FA. Physical Defects: Physical defects may include any of the following: Hand and arm anomalies; skeletal anomalies of the hips, spine, or ribs; kidney problems, including missing or horseshoe kidney; skin discolorations; small head or eyes; learning disabilities or mental retardation; gastrointestinal difficulties; defects in tissues separating chambers of the heart. Treatment Bone marrow transplantation: At the present time, this is the only long-term cure for the blood defects in FA. This treatment has many risks associated with it, and the risks are compounded in FA patients because of their extreme sensitivity to radiation and chemotherapy. FA patients often experience complications which are not routine for other transplants, such as a marked increased risk in organ toxicity and in graft-verus-host disease. Research In 1989, no FA patient had survived an unrelated donor bone marrow transplant. At one major transplant center today, success rates for these transplants are now around 70%. In 1989, no FA gene had been found. Scientists have now cloned 11 FA genes. An FA gene therapy trial is currently underway in Cincinnati. In 2003, scientists discovered that a gene for hereditary breast cancer is also an FA gene. This discovery brought major cancer researchers and FA scientists together to the benefit of both fields. In 1989, 18 researchers attended the first FA Scientific Symposium in Oregon. In 2005, the Seventeenth Annual Scientific Symposium brought 186 research scientists from all over the world to Switzerland to present and debate issues related to understanding and curing this disorder. The explosion of interest in FA confirms the importance of this disorder in understanding cancer itself.

5